Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18033 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Neil Chanchlani and 1 co-authors. Institution: Department of paediatric gastroenterology, Bristol Royal Hospital for Children, Bristol, UK. Major MEDLINE topics: Infliximab, Crohn Disease, Cost-Benefit Analysis, Gastrointestinal Agents. Cited 1 times so far (Crossref); 9 references.
Abstract (original language)
LINKED CONTENT This article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18000 and https://doi.org/10.1111/apt.18053
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of paediatric gastroenterology, Bristol Royal Hospital for Children, Bristol, UK.
- Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK.
- Department of paediatric gastroenterology, Royal Hospital for Children and Young People, Edinburgh, UK.
- Child Life and Health, University of Edinburgh, Edinburgh, UK.
Cite
APA
Chanchlani, N., & Russell, R. K. (2024). Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18033
Vancouver
Chanchlani N, Russell RK. Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18033
BibTeX
@article{Chanchlani2024,
author = {Chanchlani, Neil and Russell, Richard K},
title = {Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18033}
}
EUVIMED